Clinical trials: completed, in Guinea-Bissau
Poliovirus Vaccine, Oral, COVID
OPV as Potential Protection Against COVID-19
Since the 1960s, studies have shown that oral polio vaccine (OPV) may have beneficial non-specific effects, reducing morbidity and mortality from other infections than polio.
- Conditions
- Poliovirus Vaccine, Oral, COVID, Mortality, Morbidity
- Trial name
- NCT04445428
- Testing
- oral polio vaccine + information, Information
- Where
- Guinea-Bissau
- Volunteers
- 3,729 people
- Sponsor
- Bandim Health Project
Aids, Cdc Group I
HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Treatment: Immunization with peptide-mix and adjuvant. The vaccine should induce cellular immunity against HIV-1. Target group: Untreated healthy individuals with chronic HIV-1 infection.
- Trial name
- HIV-BIS (NCT01141205)
- Testing
- AFO-18, Saline
- Where
- 2 sites in Guinea-Bissau
- Volunteers
- 18 people
- Sponsor
- Statens Serum Institut